혈장 분획 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Plasma Fractionation Market was valued at USD 33.7 billion in 2024 and is estimated to grow at a CAGR of 6.6% to reach USD 65.3 billion by 2034. This market expansion is being shaped by the increasing usage of immunoglobulins across a range of therapeutic treatments, higher demand for sophisticated healthcare options, and continuous improvements in fractionation technologies. A significant rise in the number of patients diagnosed with genetic and immunological conditions is pushing the adoption of plasma-derived therapies. With chronic illnesses becoming more detectable through improved diagnostics, patient access to treatments requiring plasma proteins is increasing. Plasma fractionation, the industrial process used to extract and isolate critical proteins from donated blood, is at the center of this transformation.

Plasma proteins such as albumin and coagulation factors are essential in the treatment of multiple disorders. The growing frequency of autoimmune and inherited diseases is contributing to the broader use of these therapies. Increased R&D investments are further driving innovations in plasma-based treatments across diverse healthcare segments. From managing immune deficiencies to treating bleeding disorders, the applications of fractionated plasma components are expanding significantly, helping to fuel consistent demand through the forecast period.

The immunoglobulins segment accounted for a 46.8% share in 2024, reflecting strong demand for plasma-based therapies used in treating a broad range of health conditions. The segment is witnessing a surge in usage driven by a growing number of immunological and neurological diseases. Increasing off-label application of IVIg in clinical settings and its wider adoption for managing conditions like Guillain-Barre syndrome and Kawasaki disease are contributing to its dominant position in the market and supporting sustained growth.

The cold ethanol fractionation segment held a 47.9% share in 2024. The technique remains a standard in large-scale plasma processing facilities due to its efficiency, cost-effectiveness, and ability to yield high-purity plasma proteins. It is favored for extracting multiple protein types simultaneously and offers an optimal mix of safety and extraction performance. Its use is especially widespread for isolating key plasma components such as immunoglobulins and albumin.

U.S. Plasma Fractionation Market was valued at USD 10.4 billion in 2024. The country maintains a leadership position in this sector due to strong healthcare infrastructure, high awareness of plasma-based therapies, and widespread availability of donation centers. Increasing prevalence of chronic conditions and the routine use of immunoglobulins and coagulation factors in clinical care have amplified the demand for plasma-derived products. As more patients require long-term therapies, the need for reliable plasma protein supply continues to climb, bolstering U.S. market strength.

Key companies active in the Plasma Fractionation Market include Takeda, Kedrion Biopharma, Grifols, Prothya Biosolutions, GC Biopharma, SK Plasma, Kamada Pharmaceuticals, LFB Group, VIRCHOW BIOTECH PRIVATE LIMITED, Japan Blood Products Organization (JB), Intas Pharmaceuticals, Octapharma, CSL, and Taibang Biologic Group. To secure a strong foothold in the Global Plasma Fractionation Market, leading companies are implementing strategies focused on capacity expansion, strategic collaborations, and innovation in processing methods. They are increasing investments in research and development to explore new therapeutic applications of plasma-derived proteins. Many firms are also forming long-term agreements with healthcare providers and government agencies to ensure consistent demand and supply.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Method trends
  • 2.2.4 Application trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing demand for advanced treatment options
    • 3.2.1.2 Rising adoption of immunoglobulins in various therapeutic applications
    • 3.2.1.3 Increasing prevalence of respiratory and genetic disorders
    • 3.2.1.4 Technological advancements in plasma fractionation
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory policies
    • 3.2.2.2 Emergence of alternative options
  • 3.2.3 Market opportunities
    • 3.2.3.1 Favourable government strategies for self-sufficiency
    • 3.2.3.2 Growing research and development activities for plasma-derived therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technological advancements
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Plasma fractionation process overview
• 3.7 Value chain analysis
• 3.8 Albumin unit sales by region, 2024
• 3.9 Market evolution and historical context
• 3.10 Porter's analysis
• 3.11 PESTEL analysis
• 3.12 Future market trends
• 3.13 Gap analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
  • 4.2.4 Asia Pacific
  • 4.2.5 Latin America
  • 4.2.6 MEA
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Immunoglobulins
  • 5.2.1 Intravenous immunoglobulins
  • 5.2.2 Subcutaneous immunoglobulins
  • 5.2.3 Other immunoglobulins
• 5.3 Coagulation factors
  • 5.3.1 Factor VIII
  • 5.3.2 Factor IX
  • 5.3.3 Prothrombin complex concentrates
  • 5.3.4 VON WILLEBRAND factor
  • 5.3.5 Fibrinogen concentrates
  • 5.3.6 Other coagulation factor concentrates
• 5.4 Albumin
• 5.5 Protease inhibitors
• 5.6 Other plasma products

Chapter 6 Market Estimates and Forecast, By Method, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Cold ethanol fractionation
• 6.3 Chromatography
• 6.4 Centrifugation
• 6.5 Other methods

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Immunology
• 7.3 Neurology
• 7.4 Hematology
• 7.5 Pulmonology
• 7.6 Oncology
• 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Clinical research laboratories
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 LFB Group
• 10.2 CSL
• 10.3 GC Biopharma
• 10.4 Grifols
• 10.5 Intas Pharmaceuticals
• 10.6 Japan Blood Products Organization (JB)
• 10.7 Kamada Pharmaceuticals
• 10.8 Kedrion Biopharma
• 10.9 Octapharma
• 10.10 Prothya Biosolutions
• 10.11 SK Plasma
• 10.12 Taibang Biologic Group
• 10.13 Takeda
• 10.14 VIRCHOW BIOTECH PRIVATE LIMITED